NeoTool expands testing features, code set functionality of integration engine

NeoTool has released its latest version of NeoIntegrate, which continues to optimize the configure-test-manage-protect cycle for healthcare interfacing.

The company said NeoIntegrate’s newest features and functionality includes:
  • Greater interface quality through new test message manager functionality;
  • Re-usability of data transformation logic through added action list calls;
  • Expanded interface requirements with new code set translation capabilities; and
  • Ongoing interface management and insights with graphical view of message flow statistics.
The Plano, Texas-based NeoTool said the latest NeoIntegrate release offers testing features, such as new loading options that allow users to load test files as a single, unparsed message, as a file of messages, or as an individual message. In addition, the new test message manager offers testing of messages without the requirement to create customized files. Users can select messages in a file or folder for testing and store remaining messages for future use.

With the addition of action list call functionality, the company said its interface analysts configure re-usable subsets of data logic and mapping. Benefits of using the new functionality include: re-use of frequently used groups of actions; test a sub-set of actions, independent of the rest of the action list; insulate a group of actions for separate development and testing; and maintain frequently used actions.

NeoTool said NeoIntegrate’s code translation features provides the capability to productively address the varying code sets that are sent and received from diverse providers within a healthcare community. Mappings are now implemented and maintained within NeoIntegrate’s configuration settings with no more manual look-up.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.